Presented at ASCCT 2022 Next Generation Risk Assessment (NGRA) using NAMs for skin sensitization: Reproducibility and precision of the GARDskin Dose-Response assay for PoD determination of fragrance chemicals. Andy Forreryd1, […]
Presented at ASCCT 2022 The use of the GARD®skin Dose-Response assay to assess skin sensitizing potency in developing novel fragrance ingredients Tim Lindberg1, Christopher Choi2, Ulrika Mattson1 and Satoshi Sasaki3 […]
Vår verksamhet i Lund växer starkt och vi söker fler drivna medarbetare till vårt labb SenzaGen avser att bli en ledande aktör inom djurfri toxikologisk testning och driva omställningen från […]
The new standard for skin sensitization ISO 10993-10 is freshly published and now includes in vitro methods – a big step for non-animal methods in skin sensitization testing of medical […]
SenzaGen and VitroScreen have decided to join forces. The highly accurate and broadly applicable skin sensitization test platform GARD will be joined by a recognized pre-clinical CRO and leading in […]
SenzaGen has been selected to test substances from a leading global pharmaceuticals company. The pharmaceuticals company, which is one of the largest in the world, has global operations with a […]
SenzaGen now starts to collaborate with one of the world’s leading companies in the beauty and cosmetics market. With GARD™skin Dose-Response, the company wants to determine the dose at which […]
Comments to the 2020 closing and 2021 update by CEO Axel Sjöblad.
Click image to read the newsletter.
At this year’s Society of Toxicology annual meeting SenzaGen’s in vitro Medical Device test method was awarded the Best Overall Abstract Award in the Medical Device and Combination Product Specialty […]
